Declassify DOMANE

The Defense Threat Reduction (Increase) Agency’s DOMANE system is back in the news after investigative journalist George Webb announced that he intended to sue Dr. Robert Malone if Malone does not explain issues surrounding DOMANE and the products that DOMANE identified as repurposed FDA-approved treatments for COVID-19.

Here is a recent Rumble video on The Duke Report where Mr. Webb lays out his concerns with DOMANE and a potential lawsuit regarding DOMANE and Malone.

Mr. Webb has done much more research on this subject than I have. Here’s some background that I have for my subscribers.

There was a DOMANE document created December 11, 2019. To place that date in a COVID timeline, the World Health Organization identified a date of December 08, 2019, as the date of the first onset of symptoms later described as COVID-19. Many people believe the disease began earlier. That only means that the program was available in the early phases of the Plandemic.

Malone announced on the Joe Rogan show in December 2021 that DOMANE had identified famotidine as a repurposed FDA-approved therapeutic for COVID-19, and that they were moving forward with trials. Malone took famotidine in late February 2020 after contracting what he described as COVID, and announced that he had discovered the cure for COVID on LinkedIn- also in late February 2020. (The New York Times wrote an article about it in July 2020 and referenced Malone’s LinkedIn post on famotidine. LinkedIn banned Robert Malone and removed his reference to famotidine. The New York Times also inexplicably deleted their July 2020 referencing the February 2020 LinkedIn post on famotidine).

By March 20, 2020, Northwell Health was “working with” with Alchem Laboratories on famotidine and hydroxychloroquine in combination to treat COVID-19, according to a whistleblower complaint from Rick Bright (1). It is unclear to me how hydroxychloroquine came to be used in combination with famotidine at Alchem. Did DOMANE identify hydroxychloroquine as an effective and safe repurposed FDA-approved treatment, or did Alchem Laboratories and Northwell Health identify hydroxychloroquine by another method?

Malone’s colleague Michael Callahan lobbied ASPR Director Robert Kadlec to begin a study of famotidine. (Callahan was given a contract by Kadlec sometime around late January 2020. Callahan also called Malone from just outside Wuhan on January 04, and told him to get to work at Alchem, according to Malone. Callahan has claimed that he observed lower death rates associated with famotidine in Wuhan than another Merck product, omeprazole, and that this is the basis for his recommendation to Kadlec. There is no public data to support Callahan’s assertion. Malone has claimed that he did not discuss the Wuhan data with Callahan, and that his “discovery” of famotidine was within the DOMANE system. This despite the fact that Malone and Callahan were colleagues who had published papers together on Zika virus, and that Callahan called Malone from outside Wuhan and told him to get to work at Alchem. It seems very odd that they would not discuss famotidine and SARS-CoV-2. I suppose another question to ask is: when was famotidine added to the DOMANE system?)

After Callahan’s request to Kadlec, Kadlec in turn, requested that Kevin Tracey of Cold Springs Harbor Laboratory that Northwell Health submit a trial proposal for famotidine. (The contractual relationship between Cold Springs Harbor Laboratory and Northwell Health is unclear, but they have a webpage on a cancer partnership.

Tangent: Cold Springs Harbor had found a way to encode cancer into the DNA of animals by 1928, for research purposes of course, so that they could have a stock of animals with cancer necessary to do research to cure cancer.

Cold Springs Harbor began as the first Eugenics Records Office in the United States, financed by the Rockefellers.

The Rockefeller’s genetic research was transferred in large part to Germany after meeting resistance in the United States; continued in concentration camps in Germany during the Holocaust; and was transferred back to the United States after World War II with the very same German scientists. In my opinion, due to the absurd fact that safe and effective treatments for COVID-19 were blocked by forces in the United States, and the fact that mRNA vaccines, which modify human DNA, were approved, it is not unreasonable to assume that a Eugenics organization would conspire to block safe and effective therapeutics in favor of evil gene-altering ones.

On April 14, ALCHEM LABORATORIES CORP, 13305 RACHAEL BLVD, ALACHUA, FL 32615-6687, was awarded $20,747,018.00 by the Department for “a multi-site, randomized, double-blind, multi-arm historical control, comparative trials of the safety and effectiveness of hydroxychloroquine and the combination of hydroxychloroquine and famotidine for the treatment of moderate to severe COVID-19 disease.”

Which is another interesting point- hydroxychloroquine trials alone were paid for by DHHS/ASPR to Alchem. That’s what the award says - “hydroxychloroquine and the combination of hydroxychloroquine and famotidine.” I’m not sure if the hydroxychloroquine trials happened or not. HousatonicLive reported that they were unable to do the HCQ trials because Northwell did not have enough COVID patients, due to exhausting their supply of COVID patients on famotidine. I do not know if this information is correct or not.

I suppose that’s enough background to say that their is a need for the government to declassify all aspects of the DOMANE program. I’m not making much of my “theories” in this article. As I’ve said before, I’m getting very tired of theory. I’m in the mood for efforts to expose the facts that will prove exactly what happened beyond a reasonable doubt.

The government should declassify DOMANE.

Charles Wright

(1) On March 20, 2020, Dr. Kadlec wrote to the Executive Vice President of Research at Northwell Health, Dr. Kevin Tracey, to request an expedited review of the company’s clinical trial to develop a COVID-19 treatment. See letter from R. Kadlec to K. Tracey (Mar. 20, 2020), attached hereto as Exhibit 47. Northwell Health was working with Alchem Laboratories (“Alchem”) on a treatment using hydroxychloroquine in combination with famotidine, the active compound in the heartburn drug Pepcid AC. Dr. Kadlec invited Northwell Health to submit a proposal to ASPR Next and, in an unprecedented move, instructed it to “work with COVID clinical expert, Dr. Michael Callahan, in the preparation of this white paper and draft budget.” Id. Dr. Callahan is a consultant on Dr. Kadlec’s staff who was hired to advise HHS about the government’s COVID response. He is not a government employee. Yet as a consultant “who is advising or has advised the Federal Government with respect[] to a Federal agency procurement,” Dr. Callahan is prohibited from disclosing information about a contractor bid or proposal, or source selection information, before the award of a Federal agency procurement contract. See 41 U.S.C. § 2102(a)(3)(A). By directing a member of his staff to work as an agent of both the company and the government regarding the proposal, Dr. Kadlec was inviting violations of federal procurement law.